Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Clinical Hematology International|October 13, 2025
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-AnalysisJehad Almasri, Bashar Hasan, Zin Tarakji, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 12, 2023
Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6Hira Mian, Jolie Ringash, Ralph Meyer, et al.
The Oncologist|April 18, 2024
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple MyelomaHira Mian, Hsien Seow, Amaris K Balitsky, et al.
Blood Advances|September 30, 2024
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysisMohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, et al.
JCO Global Oncology|August 12, 2022
Global Myeloma Trial Participation and Drug Access in the Era of Novel TherapiesRaleigh Ayoolu Fatoki, Kelly Koehn, Amar Kelkar, et al.
Healthcare (Basel, Switzerland)|April 12, 2025
A Qualitative Study Exploring the Rehabilitation Experience of Individuals with a Previous Diagnosis of Cancer and/or Sepsis, Their Caregivers, and Health ProvidersJenna Smith-Turchyn, Christopher Farley, Anastasia N L Newman, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
Haematologica|July 13, 2023
Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort studyArleigh McCurdy, Hsien Seow, Gregory P Pond, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2024
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort StudyHira Mian, Hsien Seow, Gregory R Pond, et al.
Blood Cancer Journal|September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trialArleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Pageof 8